Skip to content
Screener

4D Molecular Therapeutics FDMT Q1 2026 earnings

Reported May 7, 2026 · After market close

Revenue$3.0MBeat by $459.5K
EPS-$1.01Miss by $0.04
Revenue estimate$2.6M
EPS estimate-$0.97

Next report

Nov 10, 2026 (in 2 months)
Revenue estimate$3.5M
EPS estimate-$1.04

Financials

Q1 2026

Income statement

See full
Revenue$3.0M+21,664%
Operating income-$73.6M-37.3%
Net income-$68.8M-43.3%
EPS (diluted)-$1.01-17.4%

Balance sheet

See full
Cash & equivalents$72.5M-45.7%
Total debt$20.5M-13.9%
Total equity$451.8M-3.8%
Total assets$512.9M-0.5%

Cash flow

See full
Operating cash flow-$68.1M-42.6%
CapEx--100%
Free cash flow-$68.1M-42.2%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$475.29M+218%
Enterprise value$423.34M+961%
P/S5.4×-6,497×

Profitability

See full
Operating margin-220.1%-110pp

Returns & leverage

See full
Debt / equity0×0.0×
Current ratio9.3×-3.0×

Segments

By geography

See full
JP$3.0M—
US$90.0K+543%

By product

See full
Collaboration And License Revenue$3.0M+21,664%

FAQ

When did 4D Molecular Therapeutics report Q1 2026 earnings?
4D Molecular Therapeutics (FDMT) reported Q1 2026 earnings on May 7, 2026 after market close.
What were 4D Molecular Therapeutics's Q1 2026 revenue and EPS?
4D Molecular Therapeutics reported revenue of $3.0M and eps of $-1.01 for Q1 2026.
Did 4D Molecular Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $2.6M by $459.5K. EPS missed the consensus estimate of $-0.97 by $0.04.
How did 4D Molecular Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 21664.3% from $14.0K a year earlier and eps declined 17.4% from $-0.86.
Where can I find 4D Molecular Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-211904) and the 10-Q periodic report (0001193125-26-211939) directly on SEC EDGAR. The filing index links above go to sec.gov.